• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

体重指数正常人群 2 型糖尿病的病因:个人体脂阈值假说检验。

Aetiology of Type 2 diabetes in people with a 'normal' body mass index: testing the personal fat threshold hypothesis.

机构信息

Magnetic Resonance Centre, Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, U.K.

Faculty of Medical Sciences Professional Services, Newcastle University, U.K.

出版信息

Clin Sci (Lond). 2023 Aug 31;137(16):1333-1346. doi: 10.1042/CS20230586.

DOI:10.1042/CS20230586
PMID:37593846
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10472166/
Abstract

Weight loss in overweight or obese individuals with Type 2 diabetes (T2D) can normalize hepatic fat metabolism, decrease fatty acid oversupply to β cells and restore normoglycaemia. One in six people has BMI <27 kg/m2 at diagnosis, and their T2D is assumed to have different aetiology. The Personal Fat Threshold hypothesis postulated differing individual thresholds for lipid overspill and adverse effects on β-cell function. To test this hypothesis, people with Type 2 diabetes and body mass index <27kg/m2 (n = 20) underwent repeated 5% weight loss cycles. Metabolic assessments were carried out at stable weight after each cycle and after 12 months. To determine how closely metabolic features returned to normal, 20 matched normoglycemic controls were studied once. Between baseline and 12 months: BMI fell (mean ± SD), 24.8 ± 0.4 to 22.5 ± 0.4 kg/m2 (P<0.0001) (controls: 21.5 ± 0.5); total body fat, 32.1 ± 1.5 to 27.6 ± 1.8% (P<0.0001) (24.6 ± 1.5). Liver fat content and fat export fell to normal as did fasting plasma insulin. Post-meal insulin secretion increased but remained subnormal. Sustained diabetes remission (HbA1c < 48 mmol/mol off all glucose-lowering agents) was achieved by 70% (14/20) by initial weight loss of 6.5 (5.5-10.2)%. Correction of concealed excess intra-hepatic fat reduced hepatic fat export, with recovery of β-cell function, glycaemic improvement in all and return to a non-diabetic metabolic state in the majority of this group with BMI <27 kg/m2 as previously demonstrated for overweight or obese groups. The data confirm the Personal Fat Threshold hypothesis: aetiology of Type 2 diabetes does not depend on BMI. This pathophysiological insight has major implications for management.

摘要

超重或肥胖 2 型糖尿病(T2D)患者减轻体重可以使肝脂肪代谢正常化,减少脂肪酸对β细胞的过度供应,并恢复正常血糖水平。六分之一的人在诊断时 BMI<27kg/m2,他们的 T2D 被认为具有不同的病因。个人脂肪阈值假说假设不同个体的脂质溢出和对β细胞功能的不良影响有不同的阈值。为了验证这一假说,20 名 BMI<27kg/m2 的 2 型糖尿病患者(n=20)进行了重复的 5%体重减轻周期。在每个周期后和 12 个月时稳定体重下进行代谢评估。为了确定代谢特征恢复正常的程度,还对 20 名匹配的血糖正常对照者进行了一次研究。在基线和 12 个月之间:BMI 下降(均值±标准差),从 24.8±0.4kg/m2 降至 22.5±0.4kg/m2(P<0.0001)(对照组:21.5±0.5);全身脂肪从 32.1±1.5%降至 27.6±1.8%(P<0.0001)(对照组:24.6±1.5)。肝脂肪含量和脂肪输出下降到正常水平,空腹血浆胰岛素也下降到正常水平。餐后胰岛素分泌增加,但仍低于正常水平。通过初始体重减轻 6.5(5.5-10.2)%,70%(14/20)的患者实现了持续的糖尿病缓解(HbA1c<48mmol/mol 且停用所有降糖药物)。纠正隐蔽性肝内脂肪过多减少了肝脂肪输出,恢复了β细胞功能,所有患者的血糖均得到改善,并且大多数 BMI<27kg/m2 的患者恢复到非糖尿病的代谢状态,正如以前超重或肥胖组所证明的那样。这些数据证实了个人脂肪阈值假说:2 型糖尿病的病因并不依赖于 BMI。这种病理生理学的见解对管理具有重大意义。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/faf7/10472166/48c5a397382c/cs-137-cs20230586-g3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/faf7/10472166/d8ddadd5d618/cs-137-cs20230586-g1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/faf7/10472166/6d823cb3beb8/cs-137-cs20230586-g2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/faf7/10472166/48c5a397382c/cs-137-cs20230586-g3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/faf7/10472166/d8ddadd5d618/cs-137-cs20230586-g1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/faf7/10472166/6d823cb3beb8/cs-137-cs20230586-g2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/faf7/10472166/48c5a397382c/cs-137-cs20230586-g3.jpg

相似文献

1
Aetiology of Type 2 diabetes in people with a 'normal' body mass index: testing the personal fat threshold hypothesis.体重指数正常人群 2 型糖尿病的病因:个人体脂阈值假说检验。
Clin Sci (Lond). 2023 Aug 31;137(16):1333-1346. doi: 10.1042/CS20230586.
2
Normal weight individuals who develop type 2 diabetes: the personal fat threshold.体重正常却患上 2 型糖尿病的个体:个人脂肪阈值。
Clin Sci (Lond). 2015 Apr;128(7):405-10. doi: 10.1042/CS20140553.
3
Type 2 diabetes and remission: practical management guided by pathophysiology.2 型糖尿病及其缓解:基于病理生理学的实用管理。
J Intern Med. 2021 Jun;289(6):754-770. doi: 10.1111/joim.13214. Epub 2020 Dec 27.
4
Mechanisms of weight loss-induced remission in people with prediabetes: a post-hoc analysis of the randomised, controlled, multicentre Prediabetes Lifestyle Intervention Study (PLIS).体重减轻诱导的前驱糖尿病缓解的机制:随机、对照、多中心前驱糖尿病生活方式干预研究(PLIS)的事后分析。
Lancet Diabetes Endocrinol. 2023 Nov;11(11):798-810. doi: 10.1016/S2213-8587(23)00235-8. Epub 2023 Sep 25.
5
Effects of weight loss and weight gain on HbA, systolic blood pressure and total cholesterol in three subgroups defined by blood glucose: a pooled analysis of two behavioural weight management trials in England.体重减轻和体重增加对按血糖定义的三个亚组中糖化血红蛋白、收缩压和总胆固醇的影响:英格兰两项行为体重管理试验的汇总分析
BMJ Open. 2025 Apr 15;15(4):e095046. doi: 10.1136/bmjopen-2024-095046.
6
Sibutramine is effective for weight loss and diabetic control in obesity with type 2 diabetes: a randomised, double-blind, placebo-controlled study.西布曲明对伴有2型糖尿病的肥胖患者的体重减轻和糖尿病控制有效:一项随机、双盲、安慰剂对照研究。
Diabetes Obes Metab. 2000 Apr;2(2):105-12. doi: 10.1046/j.1463-1326.2000.00071.x.
7
Orlistat 120 mg improves glycaemic control in type 2 diabetic patients with or without concurrent weight loss.奥利司他 120 毫克可改善伴有或不伴有体重减轻的 2 型糖尿病患者的血糖控制。
Diabetes Obes Metab. 2009 Apr;11(4):361-71. doi: 10.1111/j.1463-1326.2008.00970.x. Epub 2009 Jan 22.
8
Aetiology of type 2 diabetes: an experimental medicine odyssey.2型糖尿病的病因:一段实验医学的探索之旅。
Diabetologia. 2025 May 2. doi: 10.1007/s00125-025-06428-0.
9
Dietary carbohydrate restriction augments weight loss-induced improvements in glycaemic control and liver fat in individuals with type 2 diabetes: a randomised controlled trial.饮食碳水化合物限制增强了 2 型糖尿病患者体重减轻引起的血糖控制和肝脂肪改善:一项随机对照试验。
Diabetologia. 2022 Mar;65(3):506-517. doi: 10.1007/s00125-021-05628-8. Epub 2022 Jan 7.
10
Postprandial hyperlipidemia after a fat loading test in minority adolescents with type 2 diabetes mellitus and obesity.2型糖尿病合并肥胖的少数民族青少年进行脂肪负荷试验后的餐后高脂血症。
J Pediatr Endocrinol Metab. 2004 Jun;17(6):853-64. doi: 10.1515/jpem.2004.17.6.853.

引用本文的文献

1
Ultra-Processed Foods and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): What Is the Evidence So Far?超加工食品与代谢功能障碍相关脂肪性肝病(MASLD):目前有哪些证据?
Nutrients. 2025 Jun 24;17(13):2098. doi: 10.3390/nu17132098.
2
Exploring Therapeutic Targets for Preventing Cardiac Arrest by Modulating Dyslipidemia and 25-Hydroxyvitamin D Metabolism: A Mendelian Randomization Study.通过调节血脂异常和25-羟基维生素D代谢预防心脏骤停的治疗靶点探索:一项孟德尔随机化研究
Hum Mutat. 2025 Jun 19;2025:5536318. doi: 10.1155/humu/5536318. eCollection 2025.
3
Glycaemic and Weight Control in People Aged 65 or Younger Newly Diagnosed with Type 2 Diabetes in Spain: Insights from the PRIORITY-T2D Study.

本文引用的文献

1
Genetic and pharmacologic inhibition of ALDH1A3 as a treatment of β-cell failure.通过遗传和药物抑制 ALDH1A3 治疗β细胞衰竭。
Nat Commun. 2023 Feb 2;14(1):558. doi: 10.1038/s41467-023-36315-4.
2
Ethnic and sex differences in hepatic lipid content and related cardiometabolic parameters in lean individuals.瘦人群体中肝脏脂质含量及相关心血管代谢参数的种族和性别差异。
JCI Insight. 2022 Apr 8;7(7):e157906. doi: 10.1172/jci.insight.157906.
3
Consensus Report: Definition and Interpretation of Remission in Type 2 Diabetes.共识报告:2型糖尿病缓解的定义与解读
西班牙65岁及以下新诊断2型糖尿病患者的血糖和体重控制:PRIORITY-T2D研究的见解
Adv Ther. 2025 May 19. doi: 10.1007/s12325-025-03230-7.
4
Aetiology of type 2 diabetes: an experimental medicine odyssey.2型糖尿病的病因:一段实验医学的探索之旅。
Diabetologia. 2025 May 2. doi: 10.1007/s00125-025-06428-0.
5
Nutrition Interventions for Remission of Type 2 Diabetes: Potential Role for Diabetes-Specific Nutrition Formulas.用于2型糖尿病缓解的营养干预措施:糖尿病专用营养配方的潜在作用
Clin Diabetes. 2024 Oct 28;43(2):291-302. doi: 10.2337/cd24-0052. eCollection 2025 Spring.
6
Ultra-Processed Foods and Type 2 Diabetes Mellitus: What Is the Evidence So Far?超加工食品与2型糖尿病:目前有哪些证据?
Biomolecules. 2025 Feb 19;15(2):307. doi: 10.3390/biom15020307.
7
The Twin Cycle Hypothesis of type 2 diabetes aetiology: From concept to national NHS programme.2型糖尿病病因的双循环假说:从概念到英国国家医疗服务体系项目
Exp Physiol. 2025 Jul;110(7):984-991. doi: 10.1113/EP092009. Epub 2025 Feb 3.
8
The Causal Role of Ectopic Fat Deposition in the Pathogenesis of Metabolic Syndrome.异位脂肪沉积在代谢综合征发病机制中的因果作用。
Int J Mol Sci. 2024 Dec 10;25(24):13238. doi: 10.3390/ijms252413238.
9
Body Mass Index and Diabetes Incidence Across the Adult Lifespan: The Baltimore Longitudinal Study of Aging.成年期全生命周期的体重指数与糖尿病发病率:巴尔的摩纵向衰老研究
J Endocr Soc. 2024 Sep 5;8(11):bvae156. doi: 10.1210/jendso/bvae156. eCollection 2024 Sep 26.
10
Investigation of the risk factors associated with prediabetes in normal-weight Qatari adults: a cross-sectional study.调查与正常体重卡塔尔成年人糖尿病前期相关的风险因素:一项横断面研究。
Sci Rep. 2024 Oct 4;14(1):23116. doi: 10.1038/s41598-024-73476-8.
Diabetes Care. 2021 Aug 30;44(10):2438-44. doi: 10.2337/dci21-0034.
4
Latent Autoimmune Diabetes of Adults (LADA) Is Likely to Represent a Mixed Population of Autoimmune (Type 1) and Nonautoimmune (Type 2) Diabetes.成人隐匿性自身免疫性糖尿病(LADA)可能代表了自身免疫性(1 型)和非自身免疫性(2 型)糖尿病的混合人群。
Diabetes Care. 2021 Jun;44(6):1243-1251. doi: 10.2337/dc20-2834. Epub 2021 May 20.
5
The complex link between NAFLD and type 2 diabetes mellitus - mechanisms and treatments.非酒精性脂肪性肝病与 2 型糖尿病之间的复杂关系——机制与治疗。
Nat Rev Gastroenterol Hepatol. 2021 Sep;18(9):599-612. doi: 10.1038/s41575-021-00448-y. Epub 2021 May 10.
6
LC-MS Lipidomics: Exploiting a Simple High-Throughput Method for the Comprehensive Extraction of Lipids in a Ruminant Fat Dose-Response Study.液相色谱-质谱联用脂质组学:在一项反刍动物脂肪剂量反应研究中利用一种简单的高通量方法进行脂质的全面提取。
Metabolites. 2020 Jul 17;10(7):296. doi: 10.3390/metabo10070296.
7
Effect of intensive lifestyle intervention on bodyweight and glycaemia in early type 2 diabetes (DIADEM-I): an open-label, parallel-group, randomised controlled trial.强化生活方式干预对早期 2 型糖尿病患者体重和血糖的影响(DIADEM-I):一项开放标签、平行组、随机对照试验。
Lancet Diabetes Endocrinol. 2020 Jun;8(6):477-489. doi: 10.1016/S2213-8587(20)30117-0.
8
Time Course of Normalization of Functional β-Cell Capacity in the Diabetes Remission Clinical Trial After Weight Loss in Type 2 Diabetes.2 型糖尿病患者减肥后糖尿病缓解临床试验中β细胞功能正常化的时间过程。
Diabetes Care. 2020 Apr;43(4):813-820. doi: 10.2337/dc19-0371. Epub 2020 Feb 14.
9
Hepatic Lipoprotein Export and Remission of Human Type 2 Diabetes after Weight Loss.肝脂蛋白输出与减肥后人类 2 型糖尿病的缓解
Cell Metab. 2020 Feb 4;31(2):233-249.e4. doi: 10.1016/j.cmet.2019.11.018. Epub 2019 Dec 19.
10
Insulin resistance drives hepatic de novo lipogenesis in nonalcoholic fatty liver disease.胰岛素抵抗导致非酒精性脂肪性肝病中的肝脏从头合成脂肪。
J Clin Invest. 2020 Mar 2;130(3):1453-1460. doi: 10.1172/JCI134165.